Hope for muscle disease: Long-Term drug safety study opens
NCT ID NCT07220603
Summary
This study aims to learn about the long-term safety of an experimental drug called PGN-EDODM1 for adults with myotonic dystrophy type 1. It is open only to people who have already received this drug in a previous clinical trial. The main goal is to monitor participants for any side effects over an extended period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIUSSS du Saguenay-Lac-Saint-Jean
RECRUITINGSaguenay, Canada
Contact Email: •••••@•••••
-
Ottawa Hospital Research Institute
RECRUITINGOttawa, Ontario, Canada
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.